

DirectConnect

Inside Yale Cancer Center

August 19, 2016

Announcements

Virtual Hospice Program

We are pleased to announce that beginning on August 22, Smilow Cancer Hospital will offer our patients and their families the benefit of hospice services within our hospital setting. This new "virtual hospice" service will provide expert hospice-level care, in partnership with Regional Hospice of Western Connecticut, for high-acuity patients near the end of life, as well as support more than a year of bereavement services for their families.

The initial pilot will include two hospice beds on NP12 and two on NP14. Over the last few months, our nurses and support staff on NP12 and NP14 have undergone advanced training and education in hospice care so that they can provide this expertise to our patients. To provide physician level expertise in end-of-life care, once our patients are admitted to the hospice service, the attending of record will be a Palliative Medicine/Hospice physician from Regional Hospice. To refer to the service, please enter an "Inpatient Consult to Hospice." For more information, please contact [Kerin Adelson](#) or [Cathy Lyons](#).

Lung SPORE Grants Funded

Roy S. Herbst, MD, PhD, Associate Director for Translational Research and Principal Investigator of the Yale SPORE in Lung Cancer, has

from the desk of

Peter G. Schulam, MD, PhD

Director, Yale Cancer Center
and Physician-in-Chief,
Smilow Cancer Hospital (Interim)

**Yale
NewHaven
Health**
**Smilow Cancer
Hospital**

Yale CANCER CENTER

A Comprehensive Cancer Center Designated
by the National Cancer Institute

Recent News

Read recent articles featuring experts from
Yale Cancer Center

[News Center >>](#)

LATEST ARTICLES:

announced, along with Dr. Edward Kaftan and the grant committee, the 2016-2017 Lung SPORE Developmental Program awardees. In its second year, the SPORE awarded two additional grants with the generous support of the Beatrice Kleinberg Neuwirth Fund for Pancreatic and Lung Cancer Research, funded by Stephen and Nataly Neuwirth.

2016-2017 Lung SPORE Career Development Program Awardees

The Career Development Program seeks to develop the next generation of translational lung cancer researchers by supporting early-stage careers or enhancing those of investigators with newly defined interests in the field. It is also hoped that these projects will generate preliminary data or evidence of collaboration that may be leveraged for new NCI grant applications.

Sidi Chen -

Mentors: Drs. Andre Levchenko and Roy Herbst

Uncovering the functional roles of microRNAs in lung cancer metastasis

Carolyn Presley -

Mentors: Drs. Cary Gross and Michal Rose

End-of-Life Care in the Veteran's Health Administration vs. Fee-for-Service Medicare among Patients with Advanced Lung Cancer

Wencai Zhang -

Mentors: Drs. Frank Slack and Daniel Costa (at Boston's Beth Israel Hospital)

Overcome resistance to EGFR inhibitors with microRNA-based therapy in lung cancer

Yu Zhang - Mentors: Dr. Lieping Chen

"Immune shifting" as a potential mechanism of acquired resistance during anti-Programmed Death (PD) therapy

Yale SPORE in Lung Cancer Awards 2016-17 Developmental Research Program Funds



Are You Addicted to the Sun?

[Read More >>](#)



Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer

[Read More >>](#)



'Courage for Chloe': Local fire departments decorate trucks in honor of young girl battling cancer

[Read More >>](#)

The Developmental Research Program provides seed money to investigators proposing studies having strong multi-disciplinary and translational components and the potential to evolve into a main SPORE project. It is also hoped that these projects will generate preliminary data or evidence of collaboration that may be leveraged for new NCI grant applications.

Craig Crews

Targeted degradation of tyrosine kinase inhibitor resistant epidermal growth factor receptor mutants in lung cancer

Charles Dela Cruz, Ayman El-Guindy

Herpes viruses in Lung Cancer

Xiaomei Ma, Andrew DeWan

Genetic factors contributing to lung cancer in the pediatric population

Don Nguyen

Uncovering mechanisms of osimertinib resistance in metastasis from lung adenocarcinoma

2016-2017 Lung SPORE/ Beatrice Kleinberg Neuwirth Fund for Pancreatic and Lung Cancer Research Awardees

Sue Kaech, Paula Kavathas -

Enumeration and Characterization of Neoantigen-specific T cells in NSCLC patients undergoing immunotherapy

Narendra Wajapeyee -

Probing epigenetic vulnerability of KRAS-mutant lung cancers using functional genomics

CURE Support Grant Funded

Congratulations to Beth A. Jones, PhD, MPH, Assistant Director for Diversity and Health Equity for Yale Cancer Center, who recently received approval for a P30 CURE Supplement to support the Yale Cancer Center CURE Support Grant. The Continuing Umbrella of Research Experience



Biomarker-Driven Trials Set Pace in Lung Cancer

[Read More >>](#)



DR. ROY HERBST
CHIEF OF ONCOLOGY, SMILOW CANCER CENTER

FDA launches new regulations to keep e-cigarettes out of kids hands, regulate what manufacturers sell

[Read More >>](#)

**Join Yale Cancer Center
on Facebook**

Like us on Facebook

LATEST POSTS:

(CURE) supplement is an innovative program from the NCI that will provide invaluable support to grow relationships between the Greater New Haven community and Yale Cancer Center.

The purpose of the grant is to diversify our cancer research pipeline by providing young people from groups that are underrepresented in cancer research with hands-on experience, mentoring, and the opportunity to collaborate with research teams at YCC, while advancing science and improving cancer related outcomes for the population and patients served by Yale Cancer Center and Smilow Cancer Hospital.

[Learn More >>](#)

Notables

Barbara Burtness, MD, DART Leader for the Head and Neck Cancers Program and Co-Director for the Developmental Therapeutics Research Program, has been named Editor-in-Chief of the journal ***Cancers of the Head and Neck***. The journal launched in June and is accepting submissions.

[Learn More >>](#)

The Smilow Cancer Hospital **Head and Neck Cancers Program** represented Yale well at the **American Head and Neck Society International Meeting** last month. Presentations included:

Barbara Burtness

- The Future of Head and Neck Cancer in 10 Years: Systemic Therapy - Keynote Address
- Induction Therapy to Deintensify RT for HPV+ - Scientific Session
- The Evolving Clinical Trial Landscape in HPV Associated Head and Neck Cancer - Scientific Session

Wendell Yarbrough

When chiefs at the fire departments in Bethany, Orange, and Woodbridge, Connecticut heard about 10-month old Woodbridge resident Chloe Clemens' cancer diagnosis, they knew they had to do something. Their recently repainted fire trucks make a big statement of support for Chloe and her family! The purple shows support for patients with neuroblastoma and the gold signifies support for pediatric cancer patients. A big thank you to the fire departments, and our best wishes to Chloe and her family.



[Read More >>](#)

Join us on Thursday, September 22 to learn more about the prevention, detection, and treatment of melanoma. The symposium will be led by a multidisciplinary team of experts who will present the latest information and provide guests with an opportunity to ask questions during a panel discussion. Sponsored by Aim at Melanoma and Smilow Cancer Hospital, the event is free.

- Potential New Therapies for HPV Positive HNSCC - Scientific Session
- TGCA Review - Scientific Session

Sergey Ivanov

- Molecular insight into mucinous salivary adenocarcinoma metastases: mutations in kras, p53, and histone-modifying enzymes - poster
- The role of myb-nfib fusions in maintenance of cancer stem cells in salivary adenoid cystic carcinoma - preferred paper

Benjamin Judson

- Nasopharynx/Sinuses/Skull Base - Poster Judge

Alexandra Kejner

- Education/Care Delivery - Poster Judge

Andrew Sewell

- Parp-1 facilitates hpv16 infection and carcinogenesis in oropharyngeal squamous cell carcinoma - scientific session

Employee Profile: Brian Jin

Brian Jin, LCSW is a Clinical Social Worker at Smilow Cancer Hospital that works primarily with patients diagnosed with lung cancer. In his previous work in hospice care, he found that he connected with the cancer patients, and having experienced cancer within his own family, he is happy to have the opportunity to give back. He meets with



[More >>](#)

SMILOW CANCER HOSPITAL MELANOMA SYMPOSIUM

Thursday, September 22, 2016

55 Park Street Auditorium

[Read More >>](#)

Interested in learning how to cook? Well, we have some good news for you! There are 6 places left in the upcoming cooking class with Chef Anne Gallagher, hosted by the Smilow Cancer Genetics and Prevention program. Seating is very limited, so please call 203-200-4362 to reserve your space!



An evening of nutritional education and cooking with new friends!
 • WHEN: August 19th from 6-8 p.m.
 • WHERE: Cityseed at 817 Grand Avenue, New Haven. Parking on the street.
 • Seating is very limited. Please call ahead to

[Read](#)

[More >>](#)

Thanks to Dr. Townsend and Dr. Gaffney, cancer researchers now have a new piece of software called "PathScore" to use in analyzing large sets of data. PathScore will allow researchers across the globe to identify altered pathways across patient data, therefore allowing them a more in-depth look at their research than ever before. We're proud that Yale Cancer Center is home to experts from many fields, who all contribute

newly diagnosed patients to help them with the difficult task of adjusting emotionally, and also with any psychosocial issues that arise.

"It is very rewarding to help people through their initial overwhelming emotions and get them to a place of greater stability where they can live a life with purpose and meaning," said Brian. "Lung cancer is a challenging diagnosis because it is usually only found in the later stages. However, there have been some major breakthroughs in lung cancer treatment recently, which presents a new challenge for patients, of living with lung cancer as a chronic condition."

Brian also co-facilitates the Lung Cancer Support Group and is continually in awe of patients' resiliency and their ability to embrace life and help others. He commented that it is a privilege to see people go through so much and then want to give to others.

Bonnie Indeck,LCSW, Manager of Oncology Social Work at Smilow Cancer Hospital, commented, "Brian's calm and calming demeanor helps patients, families and staff face challenging situations with grace. He not only understands the issues that patients and families are confronted with, but is able to work with them until they have adjusted to their situation. The Thoracic Oncology Program is so fortunate to have Brian - he is an asset to the program."

Funding and Award Opportunities

All current funding opportunities are archived on the Yale Cancer Center website, and searchable by topic, funding agency, and due date. Please check the site often for new opportunities.

[Learn More >>](#)

Yale Cancer Center 2016 Pilot Grants for research in non-AIDS defining cancers in aging HIV+ populations

Yale Cancer Center is pleased to announce a Pilot Grant competition for two grants at \$120,000 (60,000 annually for two years) for a specific

to the fight against cancer by using their own expertise, whatever it may be.

Fighting cancer both in and out of the clinic



Stephen Gaffney, PhD
Associate Research Scientist
in Public Health

Our researchers aren't just

[Read More >>](#)

Another amazing story of strength and courage from one of our patients! Next month, Susan "Su" Peck, will hike "rim to rim" of the Grand Canyon to raise funds to support the American Cancer Society in honor of the care she received last year for breast cancer. Congratulations Su and good luck on your journey!



[Read More >>](#)

Congratulations to Brian Shuch, MD, for receiving a Career Development Award Grant from the National Cancer Institute. Dr. Shuch is a member of our Developmental Therapeutics Research Program, and was inspired to enter the field of prostate and urological cancers after he watched a family member battle cancer. Congratulations Dr. Shuch, and thank you for the work you do.



[Read More >>](#)

project headed by a member of Yale Cancer Center. The intention of these two grants is to support research in non-AIDS defining cancers in aging HIV+ populations, address cancer disparities in the HIV+ populations of New Haven, foster collaborations and translational activities, encourage junior faculty members to establish their career in this area and have the potential to translate into future independent NIH grant applications.

Deadline for submission is 4:00 p.m. on Thursday, August 25.
Please direct all questions to [Walther Mothes](#)
[Learn More >>](#)

SU2C CIRM CLIN 2 Grant Program

Stand Up To Cancer (SU2C) calls upon members of the SU2C community to contribute ideas for clinical research to the California Institute of Regenerative Medicine's (CIRM) CLIN 2 grant program.

In addition to traditional stem cell research, CIRM would like to support projects that involve memory t-cells, progenitor cells (e.g. monocyte-derived dendritic cells), or treatments that target cancer stem cells as their primary mechanism of action.

Deadline: Send proposals to proposals@su2c.org by September 2nd. After that date, SU2C and CIRM will review letters of intent on a monthly basis.

[Learn More >>](#)

Department of Defense Prostate Cancer Research Program Funding Opportunities for Fiscal Year 2016

The FY16 Defense Appropriations Act provides \$80 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research.

Clinical Consortium Research Site Award

Independent investigators at or above the level of Assistant Professor (or equivalent). Supports the addition of a Clinical Research Site to the Prostate Cancer Clinical Trials Consortium. Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer are encouraged.

Follow Yale Cancer Center on Twitter

[Follow us on twitter](#)

LATEST TWEETS:

 Talking to Children When a Parent Is Dying nyti.ms/2bAYU9w via @nytimeswell Parenting at a Challenging Time bit.ly/2b2q8nk

 Dr. Tara Sanft @YaleCancer discusses altering #VEGF levels on ow.ly/1M7k303kcPr

 Building a #cancer#genetics & #prevention program. bit.ly/2bA92Qt Learn about #Smilow Cancer Hospital's

 Symposium on #melanoma on 9/22. #prevention#detection & #treatment info. bit.ly/2buSZTr .@AIMatMelanoma

 Story of #courage from our patient, Susan "Su" Peck, set to hike rim to rim #grandcanyon bit.ly/2aQHREq

 Multicenter trial evaluates shave margins in #breastcancer surgery #SHAVE2 vs Partial #Mastectomy P @AneesChagpar bit.ly/2aRgANW

 Join us for a free State of the Science Summit on #breastcancer on September 15. Register now. #bcsm bit.ly/2aKaTzK

 .@BankofAmerica Team Gearing Up for @CTFRide on September 10 bit.ly/2bntF5G

 PathScore: a new web tool available from @YaleCancer for identifying altered pathways in #cancer#dat. @YaleSPH bit.ly/2bcITtu

Pre-Applications Due: September 15, 2016

[Learn More >>](#)

Susan G. Komen 2016/2017 GRADUATE TRAINING IN DISPARITIES RESEARCH (GTDR) Grants

GTDR Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

Application Due: September 2016

[Learn More >>](#)

Department of Defense Breast Cancer Research Program Funding Opportunities for Fiscal Year 2016 (FY16)

The Fiscal Year 2016 (FY16) Defense Appropriations Act provides \$120 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer.

FY16 BCRP Program Announcements and General Application Instructions for the Breakthrough Award Funding Levels 1 and 2 are anticipated to be posted on the Grants.gov website in late August 2016. Pre-application and application deadlines will be available when the Program Announcements are released.

Breakthrough Award

Funding Levels 1 and 2:

- Investigators at all academic levels (or equivalent)
- Postdoctoral fellows are eligible and encouraged to apply

Funding Levels 3 and 4:

- Independent investigators at all academic levels (or equivalent)
- Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.



The #Smilow#cancer Screening and Prevention Program at the health fair ministerio femenino #earlydetection#NHV

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

August 19; 6PM

Smilow Cancer Genetics and Prevention Program / Patient Education Program

Cityseed, New Haven

Cityseed Cooking Classes

Anne Gallagher

[Read More >>](#)

August 22; 10:45AM

Smilow Cancer Screening & Prevention Program Informational Table/CT Open

Tennis Center at Yale

Urology

[Read More >>](#)

August 25; 9AM

Therapeutic Radiology Grand Rounds

Smilow LL505

Variation in Practice Patterns and Clinical Outcomes: What Can National Data Show Us?

Henry Park, MD, MPH

[Read More >>](#)

August 25; 12PM

Yale Cooperative Center of Excellence in Hematology 2016 Seminar Series

Institute for Excellence Wing

Stem Cell Signals in Regeneration and Oncogenesis

Tannishtha Reya, PhD

[Read More >>](#)

- Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

Deadline: September 14, 2016

[Learn More >>](#)

2017 BLAVATNIK NATIONAL AWARDS FOR YOUNG SCIENTISTS

- Eligible candidates must have been born in or after 1975, no exceptions.
- Current faculty members must have earned a doctoral degree (PhD, MD, DPhil, DDS, or DVM, etc.).
- Candidates must have made significant contributions to the physical sciences and engineering, chemistry, and/or the life sciences.

Internal Deadline: September 15, 2016

[Learn More >>](#)

Melanoma Research Alliance Grants

The Melanoma Research Alliance (MRA) is pleased to announce a **Request for Proposals (RFP)** for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Young Investigator Awards, Established Investigator Awards, Pilot Awards, and Academic-Industry Partnership Awards. Application

Deadline: October 21, 2016

[Learn More >>](#)

Emerging Questions in Cancer Systems Biology (U01)

The National Cancer Institute (NCI) is sponsoring a new Cancer Systems Biology Consortium (CSBC) that aims to address challenges in cancer research through the use of experimental biology or population science combined with *in silico* modeling, multi-dimensional data analysis, and systems engineering. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches

August 26; 7:30AM

Urology Morbidity & Mortality Conference

Beaumont Room

Resident Presentation, Peer Reviewed

Toby Chai, MD

[Read More >>](#)

August 26: 12PM

Smilow Cancer Screening & Prevention Program Informational Table

New Haven Green

New Haven Healthy Start's Family Fun & Fitness Day

[Read More >>](#)

August 27; 10AM

Smilow Cancer Screening & Prevention Program Informational Table

Beulah Heights First Pentecostal Church

Beulah Heights Health Fair 2016

[Read More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

renee.gaudette@yale.edu

 Forward to a Friend

to address emerging questions in cancer initiation, progression, and treatment.

Application Receipt/Submission

Date(s): November 18, 2016 by 5:00 PM local time of applicant organization.

Letter of Intent Due Date(s): 30 days prior to the application due date.

[Learn More >>](#)

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)

This Funding Opportunity Announcement (FOA) from the NCI will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Receipt/Submission

Date(s): November 30, 2016 by 5:00 PM local time of applicant organization.

Letter of Intent Due Date(s): 6 weeks prior to the application due date.

[Learn More >>](#)

Recent Publications

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.

Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS.

J Clin Oncol. 2016 Aug 15.

[Read More >>](#)

EGFR and RB1 as Dual Biomarkers in HPV-negative Head and Neck Cancer.

Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA.

Mol Cancer Ther. 2016 Aug 9

[Read More >>](#)

Contemporary National Trends of Prostate Cancer Screening among Privately Insured Men in the United States.

Kim SP, Karnes RJ, Gross CP, Meropol NJ, Van Houten H, Abouassaly R, Shah ND.

Urology. 2016 Aug 12.

[Read More >>](#)

Proposing prognostic thresholds for lymph node yield in clinically lymph node-negative and lymph node-positive cancers of the oral cavity.

Kuo P, Mehra S, Sosa JA, Roman SA, Husain ZA, Burtness BA, Tate JP, Yarbrough WG, Judson BL. Cancer. 2016 Aug 1.

[Read More >>](#)

Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.

Kesarwani AK, Ramirez O, Gupta AK, Yang X, Murthy T, Minella AC, Pillai MM.

Oncogene. 2016 Aug 15.

[Read More >>](#)

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42.

[Read More >>](#)

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP.

Eur Urol. 2016 Aug 10.

[Read More >>](#)

Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.

Kuo P, Sosa JA, Burtness BA, Husain ZA, Mehra S, Roman SA, Yarbrough WG, Judson BL.

Cancer. 2016 Jun 15;122(12):1853-60.

[Read More >>](#)

Building a Cancer Genetics and Prevention Program.

Llor X.

Clin Gastroenterol Hepatol. 2016 Aug 13.

[Read More >>](#)

Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.

Wang D, Braiteh F, Lee JJ, Denlinger CS, Shepard DR, Chaudhary A, Lin Y, Gao L, Asakiewicz C, Nasrullah F, LoRusso P.

Cancer Chemother Pharmacol. 2016 Aug 9.

[Read More >>](#)

Racial Differences in Utilization of Breast Conservation Surgery: Results from the National CancerData Base (NCDB).

Thomas P, Killelea BK, Horowitz N, Chagpar AB, Lannin DR.

Ann Surg Oncol. 2016 Aug 8.

[Read More >>](#)

PathScore: a web tool for identifying altered pathways in cancer data.

Gaffney SG, Townsend JP.

Bioinformatics. 2016 Aug 8.

[Read More >>](#)